Akero Therapeutics, Inc.
AKRO
Clasificación en acciones
#3691
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Precio por acción
$54.65
Última sincronización: 2025-12-09
Capitalización bursátil
$4.50B
Cambio (1 día)
0.00%
Cambio (1 año)
1.94%
País
US
Comercio Akero Therapeutics, Inc. (AKRO)
Categoría
Healthcare
Historial del precio de la acción de Akero Therapeutics, Inc. (AKRO)
Precio más alto de cierre: $54.59 el 2025-12-01
Precio más bajo de cierre: $18.95 el 2019-06-01
Precio más bajo de cierre: $18.95 el 2019-06-01
Historial del precio de la acción de Akero Therapeutics, Inc. desde 2019 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -0.66% |
| 2025 | 84.69% |
| 2024 | 39.17% |
| 2023 | -53.49% |
| 2022 | 118.99% |
| 2021 | -23.63% |
| 2020 | 26.67% |
| 2019 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
